FDA told Denver telehealth seller HydraMed its website misbrands compounded semaglutide and tirzepatide with false or misleading claims.
What happened
FDA reviewed HydraMed's website, https://hydramed.com, in March 2026 and found it offers compounded semaglutide and tirzepatide products. The site's product labels show "HydraMed" as if HydraMed made the drugs, when it does not, and the site says the products come from an "FDA-approved pharmacy." FDA says both claims are false or misleading, which makes the drugs misbranded.
What FDA found
The website labels show "HydraMed" as the maker of the compounded semaglutide and tirzepatide, but HydraMed is not the compounder, so the labels mislead buyers about who made the drugs.
FD&C Act section 502(a) [21 U.S.C. § 352(a)]; 21 C.F.R. § 201.1(h)(2)The website says the compounded products come from an "FDA-approved pharmacy," but FDA does not approve or license pharmacies or outsourcing facilities, so the claim implies a government approval that does not exist.
FD&C Act sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a) and 352(bb)]Because of these false or misleading claims, the compounded drugs are misbranded and shipping them across state lines is a prohibited act.
FD&C Act section 301(a) [21 U.S.C. § 331(a)]
What FDA wants
FDA tells HydraMed to find the root causes, fix the website claims, and send a written response with the steps taken and supporting documents. The response is due within 15 business days, and FDA also asks for the names of the entities that actually make the compounded drugs plus a sample of their labeling.
Who should pay attention
- telehealth and med-spa companies marketing compounded semaglutide or tirzepatide
- compounding pharmacies and outsourcing facilities that supply such platforms
- marketing and regulatory teams that write product pages and labels for compounded drugs
This is a summary. Read the original letter on fda.gov.